Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Fund Type: Open-End Fund
  • Objective: Health Care Sector
  • Asset Class: Equity
  • Geographic Focus: China

Fortune SGAM Pharmaceutical and Bios Selection Fund

+ Add to Watchlist

FSPHBIS:CH

2.22 CNY 0.000.09%

As of 12:01:23 ET on 05/22/2015.

Snapshot for Fortune SGAM Pharmaceutical and Bios Selection Fund (FSPHBIS)

Year To Date: +81.13% 3-Month: +61.35% 3-Year: +30.05% 52-Week Range: 1.16 - 2.22
1-Month: +18.37% 1-Year: +93.62% 5-Year: - Beta vs : -

Mutual Fund Chart for FSPHBIS

No chart data available.
  • FSPHBIS:CH 2.22
  • 1M
  • 1Y
Interactive FSPHBIS Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for FSPHBIS

Fortune SGAM Pharmaceutical and Bios Selection Fund is an open-ended fund incorporated in China. The Fund seeks to achieve long-term stable return via controlling risk and liquidity. The Fund invests at least 80% of its total equity investments into pharmaceutical and bios companies listed in China.

Inception Date: 03-02-2012 Telephone: 86-21-38505888 Tel
Managers: FAN HONG-BING / WANG ZHI-WEI
Web Site: www.fsfund.com

Fundamentals for FSPHBIS

NAV (on 2015-05-22) 2.22
Assets (M) (on 2015-03-31) 1,018.58
Fund Leveraged N
Minimum Investment 1,000.00
Minimum Subsequent Investment 1,000.00

Dividends for FSPHBIS

No dividends reported

Fees & Expenses for FSPHBIS

Front Load 1.50
Back Load 1.50
Current Mgmt Fee 1.50
Redemption Fee 1.50
12b1 Fee -
Expense Ratio -

Top Fund Holdings for FSPHBIS

Filing Date: 12/31/2014
Name Position Value % of Total
Xiangxue Pharmaceutical Co Ltd 3,676,047 61,316,464 7.855%
Jiangsu Hengrui Medicine Co Lt 688,528 25,806,029 3.306%
Anhui Anke Biotechnology Group 1,814,492 24,872,497 3.186%
China National Medicines Corp 694,033 21,508,083 2.755%
Aier Eye Hospital Group Co Ltd 742,304 20,450,475 2.620%
Shanghai Kehua Bio-Engineering 808,951 17,149,761 2.197%
Guizhou Yibai Pharmaceutical C 511,348 17,063,683 2.186%
Jiangzhong Pharmaceutical Co L 819,525 16,595,381 2.126%
Hualan Biological Engineering 496,111 16,520,496 2.116%
Staidson Beijing Biopharmaceut 933,397 16,167,766 2.071%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil